Právní předpis byl sestaven k datu 03.05.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
SDĚLENÍ
Ministerstva zahraničních věcí,
kterým xx xxxx x xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx věcí č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, že xxx 1. října 2023 bylo xxxxxxxxx xxxxxxxxxx UNESCO oznámeno xxxxxxxxx nového xxxxx Xxxxxxx X - Xxxxxx zakázaných látek x xxxxx xxxxxxx xxx xxx 2024 - Xxxxxxxxxxx standard Xxxxxxxxxxx xxxxxx proti xxxxxxx xx xxxxxx.
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxx x xxxxxxx změn Přílohy X Českou xxxxxxxxxx.
Xxxx xxxxx Xxxxxxx I xxxxxxxxx v xxxxxxxx x souladu x článkem 34 odst. 3 Xxxxxx dne 1. xxxxx 2024, xxx Xxxxxx xxxxxxxxx vstoupilo x xxxxxxxx xxx 18. xxxxxx 2024 x nahradilo Xxxxxxx X xxx xxx 2023, platnou xx 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Českou xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.
Xxxxxxxx znění Přílohy X pro xxx 2024 x její xxxxxxx xx českého xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x x. XXXx. Xxxxxx, Xx.X., XX.X., x. x.
xxxxxx xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;
Xxxxxxx x. 1
Xxxxxxx xxxxxxxxxxx smlouvy xx xxxxxxx jazyka
Úvod
Seznam xxxxxxxxxx xxxxx a xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx standard v xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx text Xxxxxxx zakázaných xxxxx x xxxxx xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx v xxxxxxxxxx a xxxxxxxxxxxxx. X případě xxxxxxxxxxx xxxxxxxxxxxxx mezi anglickým x xxxxxxxxxxxx textem xxxxxxxxx xxxxx x xxxxxxxxxx.
Xxxx xxxx xxxxxxx xxxxxxx pojmy xxxxxxxxx x xxxxx Seznamu xxxxxxxxxx xxxxx x xxxxx.
Xxxxxxxx Xxx soutěži
Pokud XXXX pro xxxx xxxxx neschválila xxxx xxxxxx, je xxxxxx Xxx soutěži v xxxxxx obdobím xxxxxxxxxxx xxxxx xxxx půlnocí (xx 23:59 hodin) x xxx předcházející Xxxxxxx, xxxxx xx xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.
Xxxxxxxx stále
To xxxxxxx, že xxxx xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, jak xx xxxxxxxxxx x Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „pro xxxxx xxxxxxxx článku 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx xxxxxxx, x xxxxxxxx těch xxxxxxxxxx v Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, pokud xxxx x Seznamu xxxxxxxxx označena xxxx Xxxxxxxxxx metoda.“ Podle xxxxxxxxx k xxxxxx „Xxxxxxxxxx látky a Xxxxxxxxxx xxxxxx uvedené x článku 4.2.2 xx xxxxxx xxx xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx důležité xxxx xxxx xxxxxxxxxx xxx jiné dopingové xxxxx xxxx metody. Xxx xxxxx x xxxxx x xxxxxx, xxxxx Sportovec pravděpodobně xxxx nebo xxxxxx x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx jako xxxxx, xxxxx jsou jako xxxxxx označeny z xxxxxx xxxxxx xxxxxxx xxxxxxxxxx ve xxxxxxxxxxx xxxx rámec sportu. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx tyto xxxxx: kokain, xxxxxxxxx (xxxxxx), methylendioxymetamfetamin (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 XXXXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Specifické xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx se nevztahuje xxxxx z xxxxxxxxxxxxx xxxxxx Xxxxxxx x xxxxx není v xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx orgánem pro xxxxxxx xxxxxxx u xxxx (např. léčiva x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx byl xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx veterinární xxxxxxx), xx zakázána xxxxx.
Xxxx xxxxx zahrnuje xxxxx xxxxxxx xxxxx, xxxx xxxx BPC-157, 2,4-xxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxx (např. Reldesemtiv x Tirasemtiv).
S1 XXXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxxxx látky.
Anabolické xxxxx xxxx xxxxxxxx.
X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)
Xxx xxxxxxxxx podání, xxxx xxxx včetně:
|
• |
1-androstenediol (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol) |
• |
formebolon |
|
|
• |
1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on) |
• |
mesterolon |
|
|
• |
4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on) |
|
|
• |
4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on) |
• |
metenolon |
|
|
• |
5-androstenedion (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx) |
|
|
• |
7-xxxx-XXXX |
&xxxx;• |
xxxxxxxxxxxxxx |
|
|
• |
11ß-xxxxx-19-xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on) |
|
|
• |
19-norandrostenediol (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (metyltrienolon, 17ß-hydroxy-17ɑ-methylestra-4,9,11-trien-3-on) |
|
|
• |
Androst-4-en-3,11,17-trion(11-ketoandrostenedion, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxx (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (androsta-1,4-dien-3,17-dion) |
• |
oxandrolon |
|
|
• |
calusteron |
• |
oxymesteron |
|
|
• |
klostebol |
• |
oxymetolon |
|
|
• |
danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (dehydroepiandrosteron, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- ol) |
• |
quinbolon |
|
|
• |
dimetandrolon (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx) |
&xxxx;• |
xxxxxxxxxxx |
|
|
• |
xxx-xxxxxxxxxxxxxxxxxx (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx) |
&xxxx;• |
xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX) |
x další xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X1.2. XXXXXXX ANABOLICKÉ XXXXX
Xxxx xxxx xxxxxx:
Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, selektivní modulátory xxxxxxxxxxxxx receptorů [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), XXX-4033 (ligandrol), XXX140, X-23 x XX-11], zeranol a xxxxxxxxxx.
X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX
XXXXXXXX XXXXX (PŘI SOUTĚŽI X MIMO SOUTĚŽ)
Všechny xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxxxx látky.
Následující xxxxx x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky xxxx xxxxxxxx.
X2.1. ERYTROPOETINY (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptorů, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, např. XXXX-530, peginesatid.
S2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (XXX-6548); xxxxx.
X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.
X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx růstového faktoru xxxx (XXX-β), xxxx. xxxxxxxxxxxx; xxxxxxxxxxx.
X2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx EPO; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX HORMONY X XXXXXX UVOLŇUJÍCÍ XXXXXXX
X2.2.1 Xxxxxxx xxxxxxxxxxx testosteron x xxxx, xxxx xxxx xxxxxx:
• xxxxxxxx xxxxxxxxxxxx (CG),
• xxxxxxxxxxxx xxxxxx (LH),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (GnRH, xxxxxxxxxxx) x xxxx xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),
&xxxx;• xxxxxxxxxx x xxxx agonistické xxxxxxx.
X2.2.2 Kortikotropiny x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.
X2.2.3 Růstový xxxxxx (XX), jeho xxxxxxx x fragmenty, mimo xxxx včetně:
• xxxxxxx xxxxxxxxx hormonu, např. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,
• xxxxxxxxx xxxxxxxxx xxxxxxx, např. XXX-9604 x hGH 176–191.
S2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx jiné xxxxxx:
• hormon uvolňující xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. CJC-1293, XXX-1295, xxxxxxxxxx a tesamorelin,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x xxxxxx xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, ibutamoren (XX-677), xxxxxxxxxx, lenomorelin (xxxxxxx), xxxxxxxxxxx a xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), GHRP-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, GHRP-5 a XXXX-6].
X2.3. XXXXXXX FAKTORY X XXXXXXXXXX XXXXXXXXX XXXXXXX
Xxxx xxxx xxxxxx:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxxxxxxx růstový xxxxxx (XXX)
• xxxxxxx xxxxxx 1 podobný xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx xxxxxxx
• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• růstový xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX)
• thymosin-β4 x jeho deriváty, xxxx. TB-500
• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)
x xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx ovlivňující xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx nebo xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.
X3 BETA-2 AGONISTÉ
ZAKÁZANÉ XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxx x neselektivní xxxx-2 xxxxxxxx xxxxxx všech xxxxxxxxx izomerů xxxx xxxxxxxx.
Xxxx xxxx včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Xxxxxxxxx salbutamol: xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 hodin xx jakékoliv dávce;
• xxxxxxxxx xxxxxxxxxx: maximálně xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;
• xxxxxxxxx salmeterol: xxxxxxxxx 200 mikrogramů xx 24 hodin;
• xxxxxxxxx vilanterol: xxxxxxxxx 25 mikrogramů xx 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxx vyšším xxx 1000 xx/xx nebo xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx látky x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Sportovec xxxxxxxxx xxxxxxxxxxxxx farmakokinetickou xxxxxx, že abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (inhalační) xx do xxxx xxxxxxx xxxxxxxxx dávky.
S4 XXXXXXXXX A METABOLICKÉ XXXXXXXXXX
XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)
Xxxxxxxx xxxxx ve xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.
Xxxxx xxxxxxxx xx xxxx X4.3 x X4.4 jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxxx hormonové a xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
X4.1. INHIBITORY AROMATÁZ
Mimo xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on) |
• |
androsta-3,5-dien-7,17-dion (xxxxxxxxx) |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX ESTROGENOVÝCH XXXXXXXXX (XXXXX)]
Xxxx xxxx včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. XXXXX ZABRAŇUJÍCÍ XXXXXXXX XXXXXXXXX XXXXXXXX XXX
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X |
• |
xxxxxxxxxx xxxxxxxxxx, např.: |
|
|
• |
konkurenty xxxxxxxxx xxxxxxxx XXX, např.: |
- xxxxx snižující xxxx xxxxxx xxxxxxx myostatinu |
||
|
- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031) |
- proteiny xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx xxxxxxxxx aktivinu XXX (xxxx. xxxxxxxxxx) |
- xxxxxxxxxx xxxxxxxxxxxxxx myostatin xxxx prekurzory (xxxx. xxxxxxxxxxx, domagro xxxxx, xxxxxxxxxxxxx, stamulumab) |
S4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného xxxxxxxxx xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, XX501516) x agonisté Xxx-xxxɑ , např. XX9009, XX9011
X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx
X4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 DIURETIKA A XXXXXXXXX XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX I XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Specifické xxxxx.
Xxxxxxx diuretika x xxxxxxxxx látky, xxxxxx xxxxx optických izomerů, xxxx. x- x x-, jsou xxxxxxxx.
Xxxx xxxx včetně:
• Xxxxxxxxx, xxxx xxxx.:
xxxxxxxxxxxx; amilorid; xxxxxxxxx; kanrenon; chlortalidon; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxx; xxxxxxxxx; spironolakton; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;
• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, xxxx.:
xxxxxxx, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;
• Xxxxxxxxxxx;
• Xxxxxxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými biologickými xxxxxx.
XXXXXXX
• xxxxxxxxxxx; pamabrom; x lokální xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx karboanhydrázy (xxxx. xxxxxxxxxx, xxxxxxxxxxx);
• xxxxxxx podání felypresinu x xxxxx xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx prahovým xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, katinu, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Soutěži xx xxxxxxx x xxxxxxxxxx xxxx xxxxx maskovací xxxxxx (kromě xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxx anestezii), xxxx xxxxxxxxx xx Pozitivní xxxxxxxxxxx xxxxx (AAF), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx výjimku (XX) xx xxxx xxxxx xxxxx k xx, která xxx xxxx udělena xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ METODY
ZAKÁZANÉ XXXXX (PŘI XXXXXXX X MIMO SOUTĚŽ)
Všechny xxxxxxxx xxxxxx x xxxx třídě xxxx Xxxxxxxxxxxx s výjimkou xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX X XXXX X KREVNÍMI XXXXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, allogenní (xxxxxxxxx) xxxx heterologní krve xxxx produktů x xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx s výjimkou xxxxxxxx xxxxxx nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy xxxxxxxxx x registrovaném xxxxxxxxx xxxxxx.
X1.2. Umělé xxxxxxxxx xxxxxx, přenosu xxxx xxxxxxx xxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; efaproxiral (RSR13); xxxxxxxxx a modifikované xxxxxxxxxxxxx produkty, např. xxxxxx náhražky xx xxxx hemoglobinu x xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x xxxxxxxx xxxxxxxxxxx xxxxxxx inhalací.
M1.3. Jakákoliv xxxxx xxxxxxxxxxxxxxx manipulace x krví xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.
X2. CHEMICKÁ X XXXXXXXXX MANIPULACE
Zakázané xx xxxxxxxxxxx:
X2.1. Podvádění xxxx Xxxxx x xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. přidáním xxxxxxx xx Xxxxxx.
X2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 hodin xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.
X3. XXXXXX X XXXXXXX DOPING
Z xxxxxx potencionálního xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
X3.1. Xxxxxxx xxxxxxxxxx kyselin nebo xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx sekvence xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx mechanismem. Xx mimo jiné xxxxxxxx xxxxxxxxxxx xxxxx xxxx, umlčování genů x xxxxxxxxxxx přenosů xxxx.
X3.2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.
X6 STIMULANCIA
ZAKÁZANÉ PŘI XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky x výjimkou látek xxxxxxxxx x X6.X, xxx jsou Xxxxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)
Xxxxxxx xxxxxxxxxxx, xxxxxx xxxxx xxxxxxxxx izomerů, xxxx. x- x l-, xxxx xxxxxxxx.
Xxxxxxxxxxx xxxxxxxx:
X6.X: XXXXXXXXXXXX STIMULANCIA
|
• |
adrafinil |
• |
fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, který xxxx xxxxxxxx xxxxxx x xxxxx xxxxxx, je Xxxxxxxxxxx látkou.
S6.B: XXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-dimetylpentylamin) |
• |
fenbutrazát |
• |
oxilofrin (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-dimetylamylamin, 1,3 XXXX, metylhexanamin) |
• |
heptaminol |
• |
pentetrazol |
||
|
• |
4-methylpentan-2-amin (1,3-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxx (xxxxxxxxx) |
• |
xxxxxxxxxxx a xxxx xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-dimetylpentylamin, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxx1) |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
|
• |
xxxxxxx x xxxx xxxxxxx, např. xxxxxxxx, metedron x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (dimetylamfetamin) |
• |
metylendioxymetamfetamin |
• |
selegilin |
||
|
• |
efedrin3) |
• |
metylefedrin3) |
• |
sibutramin |
||
|
• |
epinefrin (adrenalin)4) |
• |
metylnaftidát [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx] |
• |
xxxxxxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx
XXXXXXX
• xxxxxxxx;
• xxxxxxxx xxxxxxxxxxx x xxxxxxx jejich kožního, xxxxxxx, xxxxxx nebo xxxxxx xxxxxxx (např. xxxxxxxxxx, klonazolin, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, tramazolin, xylometazolin) x xxxxxxxxxxx xxxxxxxx xx Monitorovacího programu 20245).
X7 NARKOTIKA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxx xxxxx x této xxxxx: diamorfin (xxxxxx)
Xxxxxxxxxxx xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x x, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x jeho xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 XXXXXXXXXXX
XXXXXXXX XXX XXXXXXX
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Specifické xxxxx. Návykové xxxxx x xxxx sekci: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx xxxxxxxx x syntetické xxxxxxxxxxx xxxx xxxxxxxx, xxxx.
• x konopí (hašiš, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx
• xxxxxxxx x xxxxxxxxxx tetrahydrokanabionoly (XXX)
• xxxxxxxxxx kanabinoidy napodobující xxxxxx THC
VÝJIMKY
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX PŘI SOUTĚŽI
Všechny xxxxxxxx látky x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx xxxxxx.
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx xxxxxxxx |
||
|
• |
xxxxxxxx |
• |
xxxxxxxxxxxxx |
||||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxxxxx |
XXXXXXXX
• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) nejsou zakázány, xxxxx xx xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx xxxxxxxx.
X1 BETA-BLOKÁTORY
ZAKÁZANÉ X XXXXXXXX XXXXXXXX
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx látky.
Beta-blokátory xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx a kde xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.
• lukostřelba (XX)*
• xxxxxxxx/xxxxxxxxxxxx (FIS) – skoky xx xxxxxx, xxxxxxxxxxx skoky / U-rampa a xxxxxxxxx X-xxxxx / xxx xxx
• automobilový xxxxx (FIA)
• xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx volného potápění, xxxx xxxxxxxx x xxxxxxx xx terč
• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• xxxxx (WDF)
• xxxx (XXX)
• xxxxxxxx (XXX)
• xxxxxxx (XXXX, XXX)*
* zakázané xxxx Xxxx soutěž
Mimo xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx jazyce
1) xxxxx (x-xxxxxxxxxxxxxxxx) a jeho x-xxxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx x moči xxxxx xxx 5 xxxxxxxxxx x 1 xx.
2) xxxxxxxxxxxxx: xxxxxxxx pouze xxx xxxxxxxxxxx x xxxx xxxxx než 150 mikrogramů x 1 ml.
3) xxxxxxx x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx v xxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx.
4) xxxxxxxxx (xxxxxxxxx): xxxx zakázáno xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx podávání x xxxxxxxxx xxxxxxxxxx.
5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, pipradrol x xxxxxxxx: tyto xxxxx xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024 x nejsou xxxxxxxxxx xx Zakázané xxxxx.
Informace
Právní xxxxxxx x. 19/2025 Xx. xxxxx xxxxxxxxx xxxx 28.1.2024.
Xxxxx xxxxxxxxxxxx xxxxxxxx norem xxxxxx právních xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu